INTRODUCTION
Several randomized controlled trials have shown that autologous stem cell transplant (Auto-SCT) is superior to conventional chemotherapy in multiple myeloma (MM). [1] [2] [3] As such, Auto-SCT became the standard of care, and MM is the most common indication for Auto-SCT. 4 Its superiority has been reconfirmed in the era of novel agents. 5 However, most trials restricted eligibility for Auto-SCT to patients younger than 65 years. With a median age at diagnosis of MM is 66 years, 6 this age restriction limits accessibility to Auto-SCT for a large proportion of patients. Nevertheless, several transplant centers have reported the feasibility and safety of Auto-SCT in MM patients older than 65 years. [7] [8] [9] Survival benefit was demonstrated in some studies through case-control matching 7, 10, 11 or longitudinal design. 12, 13 In this study, we evaluated the outcome of stem cell mobilization and transplant for MM patients 70 years or older. To assess changes in efficacy and toxicity over time, the study cohort was divided into two time periods, 1998 to 2006 and 2007 to 2015.
MATERIALS AND METHODS
From the institutional transplant registry, 207 consecutive MM patients who were 70 years or older at Auto-SCT (study cohort) were identified. The study cohort was compared with 1764 patients from the registry who were younger than 70 years at Auto-SCT (median age, 59 years; interquartile range (IQR), 53-64 years). All patients had provided informed consent for the use of their medical records. The Mayo Clinic Institutional Review Board approved this study.
Stem cell mobilization
Mobilization and transplant management at our institution have been previously described. 14, 15 All mobilizations were performed with G-CSF SC (10 μg/kg/day). G-CSF was given alone or after cyclophosphamide (CY) (1.5 g/m 2 daily for two consecutive days) or with plerixafor (routinely available since 2009). The goal was to collect 3 × 10 6 progenitor cells/kg for single transplant, given the age of the patients (achieved in 98.5% of patients; all patients yielded more than 2 × 10 6 cells/kg).
Conditioning regimen, stem cell reconstitution and supportive care
Full-dose melphalan (200 mg/m 2 ) or reduced-dose melphalan (140 mg/m 2 ) was given at the physician's discretion, depending on patient general fitness, co-morbidities and renal function. Auto-SCT was performed as an outpatient procedure, requiring a caregiver and a stay near the hospital throughout the transplant period. Patients were followed up daily in a designated outpatient unit. Patients were admitted for uncontrolled fever, poor intake, intractable pain from mucositis that necessitated parenteral medication, decrease in performance status or arrhythmia.
Patients returned on day 100 post transplant for reevaluation, which included serum and urine studies and bone marrow examination.
Response evaluation
Response was determined according to the International Myeloma Working Group response criteria 16 and was evaluated before and after Auto-SCT. The best response after Auto-SCT was used for post-Auto-SCT response evaluation. PFS and overall survival (OS) were calculated with the Kaplan-Meier method; differences between groups were calculated with the log-rank test. Multivariate analysis for factors affecting survival was performed with the Cox proportional hazards model. We included the following variables in the univariate and multivariate models for PFS and OS: sex, transplant period, disease status (newly diagnosed or relapsed disease), response before Auto-SCT, creatinine clearance at transplant, International Staging System (ISS) stage, bone marrow plasma cells at diagnosis, melphalan conditioning dose and response after transplant.
All statistical analysis was performed with JMP software (SAS Institute Inc.) with statistical significance set at Po0.05. Table 1 . Seventy-six percent of patients underwent Auto-SCT for newly diagnosed disease, while 24% were exposed to more than one line of treatment before Auto-SCT, with no difference between periods (P = 0.35) or when compared with patients younger than 70 years (P = 0.28). Achievement of a partial response or better before transplant was similar in 1998-2006 and 2007-2015 (60.7% vs 71.5%, respectively; P = 0.14). However, the rate of a very good partial response (VGPR) or better before Auto-SCT nearly doubled between periods (16.1% vs 30.5%, respectively; P = 0.03).
RESULTS
Stem cell collection The median time from diagnosis to stem cell collection was 6.3 months (range, 0.2-219 months). Stem cell collection was performed with G-CSF alone in 40% of patients, G-CSF and plerixafor in 39% of patients, and G-CSF in combination with CY in 21% of patients. When mobilization was more than 12 months after diagnosis, patients were more likely to require two mobilizing agents compared with mobilization within 12 months after diagnosis (72.7% vs 57.2%, respectively; P = 0.09).
G-CSF/CY mobilization was more frequent in 1998-2006 compared with 2007-2015 (43% vs 12.5%; Po 0.001). Seventyseven percent of patients who were mobilized with G-CSF/CY had no response to their last regimen. With G-CSF/plerixafor mobilization, the median number of plerixafor doses was 2 (range, [1] [2] [3] [4] [5] . Patients who received prior radiotherapy were more likely to require plerixafor compared with patients who did not receive prior radiotherapy (27.5% vs 13.4%; P = 0.01). The median number of apheresis sessions was 2, similar to the younger cohort, but fewer apheresis sessions were performed on average in the study cohort compared with the younger cohort (mean, 2. Conditioning and stem cell infusion The median time from diagnosis to transplant was 7.4 months (range, 3.1-219 months), similar to the younger cohort (7.2 months; P = 0.41). Conditioning with full-dose melphalan (200 mg/m 2 ) was given to 55% of patients compared with 93% in the younger cohort (P o0.001). Of the study patients who received reduced-dose melphalan, 30% had an eGFR of 50 mL/min/1.73 m 2 at transplant; four of them were receiving hemodialysis at transplant. In a multivariate analysis performed on the study cohort, the following features were associated with the use of reduced-dose melphalan: age (odds ratio (OR), 1.2 for each 1-year increment; 95% CI, 1.01-1.4; P = 0.02), eGFR o50 mL/min/ ); 69% were infused with all their collected cells.
Engraftment and transfusion requirements Median time to neutrophil engraftment was 14 days (IQR, 13-16 days) and to platelet engraftment 15 days (IQR, 14-17 days). Time to engraftment did not differ between patients who received full-dose melphalan and patients who received reduced-dose melphalan (for neutrophil engraftment, P = 0.96; for platelet engraftment, P = 0.44). Time to neutrophil and platelet engraftment did not differ between the study cohort and the younger cohort.
In the 30 days after stem cell infusion, patients were transfused with a median of 2 units of packed RBC and 2 units of platelets Cardiac arrhythmia. Atrial arrhythmia, primarily atrial fibrillation or flutter with rapid ventricular response, developed in 22.4% of patients. Arrhythmias occurred at a median of 8 days (IQR, 4-10 days) after stem cell infusion. No difference was noted in the rate of arrhythmia between the two periods (P = 0.79). The frequency of arrhythmia was not influenced by the conditioning dose (P = 0.76). Only 12% of patients who had arrhythmia during transplant had a prior history of a similar event. Neutropenic fever (risk ratio, 2.3; 95% CI, 1.1-4.6; P = 0.01) and forced expiratory volume in 1 s (FEV 1 ) less than 90% (risk ratio, 1.2; 95% CI, 1.01-1.38; P = 0.02) were significantly associated with a risk of cardiac arrhythmia. Most cases resolved with medical treatment.
Other complications. Fourteen patients (7%) had engraftment syndrome; Clostridium difficile colitis developed in 12 patients (6%), but none required intervention other than antibiotic treatment. Six patients had venous thromboembolic events, and all were treated medically.
Two patients (1%) died within 100 days after transplant. One patient, conditioned with full-dose melphalan, died of CMV pneumonitis on day 25. The other patient, conditioned with reduced-dose melphalan, died of failure to thrive at day 95. In comparison, the treatment-related mortality rate for the younger cohort was 1.4% (P = 0.6).
Hospitalization Sixty-four percent of patients were hospitalized during transplant (two patients solely for the lack of a caregiver). In comparison, 55% of the younger cohort required hospitalization (P = 0.01). The median length of stay for the hospitalized patients in the study cohort was 8 days (IQR, 4-12 days), similar to the median for the younger cohort (7 days; IQR, 5-13 days; P = 0.52). Patients in 2007-2015 had a shorter median hospital stay compared with patients in 1998-2006 (6 vs 9 days; P o0.001). Intensive care unit admission occurred at similar rates for these 2 periods (18.5 vs 16.7%; P = 0.78), and 69% of intensive care unit admissions were for observation for cardiac arrhythmias. On a multivariate analysis, the factors associated with prolonged hospitalization (47 days) were occurrence of neutropenic fever (OR, 3.2; 95% CI, 1.4-7.6; P = 0.004), induction of cardiac arrhythmia (OR, 2.6; 95% CI, 1.3-5.4; P = 0.01), transplant period 1998-2006 (OR, 2.9; 95% CI, 1.5-6; P = 0.002) and eGFR less than 50 mL/min/1.73 m 2 (OR, 3; 95% CI, 1.3-7; P = 0.01).
Response and survival Response data are presented in Table 2 . The overall response rate after Auto-SCT was 93.2%, with no significant difference between the two periods (P = 0.62). The response rate was higher in the fulldose melphalan subgroup compared with the reduced-dose melphalan (96.5% vs 89.1%; P = 0.03). Stringent complete response (sCR) was reached by 27.3% of patients after Auto-SCT. On multivariate analysis, the only parameter that affected the ability to obtain sCR after Auto-SCT was achievement of VGPR or better before transplant (OR, 17.3; 95% CI, 6.7-50.6; P o0.0001), with fulldose melphalan only marginally associated with a higher sCR probability after Auto-SCT (OR, 2.4; 95% CI, 0.9-6.5; P = 0.08).
The study population consisted of newly diagnosed patients and patients with relapsed disease, so for homogeneity, survival curves were restricted to newly diagnosed patients. In the older cohort, median PFS was 33.5 months, which was comparable to PFS in the younger cohort (33.8 months; P = 0.91). The median OS in the older cohort was 6.1 years compared with 7.8 years in the younger cohort (P = 0.11) (Figure 1 In the study cohort, achievement of at least VGPR before Auto-SCT was associated with marginally improved PFS and OS compared with less than VGPR before SCT (for PFS: median, 45.2 vs 31.5 months; Abbreviations: eGFR = estimated glomerular filtration rate; PR = partial response; sCR = stringent complete response; SCT = stem cell transplant; VGPR = very good partial response.
Autotransplant in older multiple myeloma patients E Muchtar et al P = 0.05) (for OS: median, 9.3 vs 5.8 years; P = 0.13). After Auto-SCT, patients who achieved sCR had better PFS and OS than those who achieved less than sCR (for PFS: median, 80.8 vs 29.7 months; Po 0.001) (for OS: median, 10.1 vs 5.9 years; P = 0.009) (Figure 2) . In a univariate analysis, the following variables were significantly associated with a decreased PFS: male sex, transplant period 1998-2006, relapsed disease state, attainment of less than VGPR before Auto-SCT and attainment of less than sCR after transplant (Table 3) . In a univariate analysis, inferior OS was associated with the following variables: male sex, transplant period 1998-2006, ISS stage III (vs ISS stages I or II), achievement of less than VGPR before Auto-SCT and achievement of less than sCR after Auto-SCT. In a multivariate analysis, shorter PFS was predicted by male sex, transplant period 1998-2006, relapsed disease state and attainment of less than sCR after transplant. In comparison, predictors for shorter OS in a multivariate analysis were transplant period 1998-2006 and ISS stage III.
Maintenance therapy Maintenance therapy was given for 24.1% of patients following auto-SCT, with similar rates for newly diagnosed and relapsed patients (25 and 21.3%, respectively; P = 0.6). Maintenance regimens were mainly bortezomib-based (45%) or lenalidomide-based (39%). Maintenance was given exclusively in the 2007-2015 period. When analysis was restricted to the 2007-2015 period, maintenance treatment, as compared with observation, was associated with improved PFS (median 60.7 vs 29.1 months, respectively; P = 0.01), with only a trend to a survival advantage (median 125.6 vs 85.5 months; P = 0.13).
DISCUSSION
This study is the largest single-center report on the use of Auto-SCT in elderly patients. It is also characterized by a higher age threshold than most other studies, thus showing more convincingly the feasibility and safety of Auto-SCT in the elderly. We have shown that patients aged 70 years and up to 76 selected for Auto-SCT have non-inferior PFS and OS compared with younger patients. In addition, while infection control is better in elderly patients in recent years, the rate of cardiac arrhythmia remains high and unchanged over time, raising the need for preventive measures.
Despite the lack of randomized data for Auto-SCT in elderly patients, its application in the elderly has increased because of the growing experience with Auto-SCT in general, improved supportive care and better stem cell mobilization. 13, 17 Another important factor is the introduction of reduced-dose conditioning, shown to be better tolerated in elderly patients and still yield beneficial results, comparable to conditioning with melphalan 200 mg/m 2 . 1 We previously showed that improved survival of MM patients was seen mainly among patients older than 65 years, while younger patients showed no survival improvement. 18 This selective outcome improvement is probably associated with both the increased use of Auto-SCT in elderly patients in our institution as well as the introduction of novel agents that broadly extended the treatment options in this age-defined population. Eight percent of all transplants in 1998-2006 was in patients 70 years or older, and this rate increased to about 13% in 2007-2015, a relative increment of 65%. We have found comparable outcomes in PFS and OS between patients 70 years or older and patients younger than 70 years. Those outcomes were shown specifically for newly diagnosed patients, who comprise most of the patients in the present study. PFS improved by a similar magnitude for both age groups between the two periods (1998-2006 vs 2007-2015) (Supplementary Figure) . OS by transplant period also improved for both groups but was more pronounced for patients ⩾ 70 years, suggesting better patient selection and peri-transplant management of this challenging group of patients.
Only 40% of patients underwent mobilization with G-CSF alone, whereas the remaining patients required mobilization with either cyclophosphamide (21%) or plerixafor (39%). Such a high requirement for a second mobilization agent has not been reported for younger MM patients and likely reflects the effect of age on mobilization capacity. 19, 20 Cyclophosphamide was used to mobilize stem cells for refractory disease in earlier years to reduce the precollection tumor burden. In comparison, plerixafor was used in late mobilizations (412 months from diagnosis) and in patients who had previously received radiotherapy. For mobilization, the CD34 + yield with G-CSF/plerixafor was similar to that with G-CSF alone (6.23 × 10 6 /kg vs 5.66 × 10 6 /kg). As evidenced from randomized controlled trials demonstrating a higher CD34 + yield when plerixafor is added to G-CSF, the comparable CD34 + yield between these subgroups probably reflects patient selection for plerixafor. In contrast, patients who received G-CSF/CY yielded more CD34 + cells, as previously reported. 21, 22 Elderly patients are more likely to face toxic effects from the transplant. 13 Bacteremia rates decreased from 1998-2006 to 2007-2015, reflecting enhanced infection control measures. Although hospitalization occurred more frequently for the older cohort compared with the younger cohort, the duration of hospitalization was similar between groups, suggesting that the severity of major complications was similar between groups, which is also reflected in a comparable treatment-related mortality. However, nearly half the older patients received Autotransplant in older multiple myeloma patientsreduced-dose melphalan conditioning, compared with only 7% of patients younger than 70 years. Therefore, decreasing the dose of melphalan for conditioning may reduce excessive toxicity in the elderly. The melphalan dose was adjusted because of reduced eGFR in only 30% of patients. Therefore, the conditioning dose should not be determined solely by renal function. In the past years, awareness to elderly patients' frailty has led to formation of geriatric indices for treatment considerations. 23, 24 Whether these indices can help in guidance of the conditioning dose selection is a relevant question. In our view it will require development of a Autotransplant in older multiple myeloma patients E Muchtar et al specific index, as the current indices are generalized to the elderly population, thus may not be sensitive enough to appropriately select patients who are transplant eligible.
One of the important complications observed in the present study was the development of cardiac arrhythmia. This required hospitalization for rate control, including intensive care unit admission for monitoring. Only 12% of those patients had a prior history of arrhythmia; therefore, prediction of patients at risk of arrhythmia is challenging. A reduced FEV 1 was a predictor for atrial arrhythmias, which has also been shown to be a risk factor for atrial fibrillation in the general population. 25, 26 Cardiac toxicity from melphalan, high prevalence of fever, electrolyte imbalance and change in regular medications (such as temporarily halting β-blocker for hypotension) are potential drivers for the cardiac arrhythmias development in the peri-transplant period. A high rate of atrial fibrillation has been reported with Auto-SCT in an inpatient setting 27 and among patients with renal impairment. 28 We observed no change in this complication rate over the years; this finding emphasizes that, unlike infectious complications, the prevention of cardiac arrhythmias has not been adequately addressed. Investigation of other risk factors for arrhythmia is warranted to promote preventive measures in a more focused manner. Drug therapy, such as amiodarone or β-blockers, is probably warranted for prevention in high-risk patients, but the appropriate selection for this intervention needs to be clarified. Our study limitations include its retrospective design, lack of comparable data among patients younger than 70 (such as rate of several complications, including cardiac arrhythmia) and lack of standardized approach in the selection of the melphalan dose.
In conclusion, with proper selection Auto-SCT is safe in MM patients 70 to 76 years old. Like younger patients who have been studied in randomized controlled trials, older patients appear to benefit from Auto-SCT. Reduced-dose melphalan is required in many of these older patients to minimize toxicity. Cardiac arrhythmia was common and required urgent intervention in many instances; because the incidence of cardiac arrhythmia has been stable over time, a preventive strategy in patients deemed high risk for this complication is warranted and requires further study. In light of these results a randomized trial comparing standard treatment with auto-SCT in elderly patients eligible for transplant is warranted.
